lead plaintiff deadline

Rosen Law Firm announces securities class action against Endeavor Group Holdings ($EDR) alleging false merger disclosures. Investors must act before March 18, 2026 lead plaintiff deadline.

Rosen Law Firm files securities class action against $FBRT, alleging false statements about dividend sustainability. Lead plaintiff deadline set for April 27, 2026.

Rosen Law Firm filed a class action lawsuit against $ODD for allegedly making false statements about advertising partner algorithm changes that inflated customer acquisition costs.

Rosen Law Firm urges $PLUG investors to join class action lawsuit by April 3, 2026 deadline alleging false statements about DOE funding.

Rosen Law Firm urges Richtech Robotics ($RR) investors to file claims by April 3, 2026 in lawsuit alleging false Microsoft partnership statements.

Rosen Law Firm alerts investors in multiple securities litigation cases, including $PMI, urging them to secure counsel before critical claim deadlines.

Rosen Law Firm urges $PSFE investors to join securities class action alleging false statements on high-risk exposure and credit losses. Lead plaintiff deadline April 7, 2026.

Securities lawsuit filed against $BYND alleges false statements on asset values. Investors have until March 24 deadline to join class action.

Securities lawsuit filed against $RGNX for allegedly misleading investors about RGX-111 gene therapy efficacy and safety. Lead plaintiff deadline April 14, 2026.

Snowflake faces securities lawsuit alleging undisclosed product impacts; stock fell 18.14% after February 2024 disclosure. Lead plaintiff deadline: April 27, 2026.

Aquestive Therapeutics faces securities class action over alleged false FDA approval statements for Anaphylm drug. Stock fell 37% after January 2026 NDA rejection.

Securities class action filed against $CWH for allegedly misleading statements on inventory management. Stock fell sharply in Q3-Q4 2025; investor deadline set for May 11, 2026.

Nektar faces securities litigation over alleged misstatements about REZOLVE-AA trial enrollment practices. Stock fell 7.77% after trial failure announcement.

Eos Energy Enterprises faces securities class action over $35.8M revenue shortfall, missing 2025 guidance by 24-30%. Stock fell 39.4%; investors have until May 5, 2026 to join suit.

Securities class action filed against $RARE over alleged misstatements about setrusumab drug efficacy. Failed clinical trials triggered 25-42% stock declines. Investor deadline: April 6, 2026.

Securities class action filed against $SLNO alleging false statements about DCCR drug safety. Investors must claim lead plaintiff status by May 5, 2026.

Class action lawsuit filed against $NAAM alleges October 2025 IPO prospectus contained false statements about sales and marketing expenses. Lead plaintiff deadline: April 24, 2026.

Rosen Law Firm urges MREO investors to join class action over alleged misleading statements regarding setrusumab Phase 3 trial failures.

Rosen Law Firm urges Masonite investors to join class action lawsuit alleging material omissions regarding Owens Corning acquisition and share repurchases.

NuScale Power faces securities lawsuit alleging misrepresentations about commercialization partner ENTRA1's nuclear experience. Lead plaintiff deadline: April 20, 2026.